FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385872145> ?p ?o ?g. }

• W4385872145 abstract "Abstract Background Glioblastoma patients commonly develop resistance to temozolomide chemotherapy. Hypoxia, which supports chemotherapy resistance, favors the expansion of glioblastoma stem cells (GSC), contributing to tumor relapse. Because of a deregulated sphingolipid metabolism, glioblastoma tissues contain high levels of the pro-survival sphingosine-1-phosphate and low levels of the pro-apoptotic ceramide. The latter can be metabolized to sphingosine-1-phosphate by sphingosine kinase (SK) 1 that is overexpressed in glioblastoma. The small molecule SKI-II inhibits SK and dihydroceramide desaturase 1, which converts dihydroceramide to ceramide. We previously reported that SKI-II combined with temozolomide induces caspase-dependent cell death, preceded by dihydrosphingolipids accumulation and autophagy in normoxia. In the present study, we investigated the effects of a low-dose combination of temozolomide and SKI-II under normoxia and hypoxia in glioblastoma cells and patient-derived GCSs. Methods Drug synergism was analyzed with the Chou-Talalay Combination Index method. Dose–effect curves of each drug were determined with the Sulforhodamine B colorimetric assay. Cell death mechanisms and autophagy were analyzed by immunofluorescence, flow cytometry and western blot; sphingolipid metabolism alterations by mass spectrometry and gene expression analysis. GSCs self-renewal capacity was determined using extreme limiting dilution assays and invasion of glioblastoma cells using a 3D spheroid model. Results Temozolomide resistance of glioblastoma cells was increased under hypoxia. However, combination of temozolomide (48 µM) with SKI-II (2.66 µM) synergistically inhibited glioblastoma cell growth and potentiated glioblastoma cell death relative to single treatments under hypoxia. This low-dose combination did not induce dihydrosphingolipids accumulation, but a decrease in ceramide and its metabolites. It induced oxidative and endoplasmic reticulum stress and triggered caspase-independent cell death. It impaired the self-renewal capacity of temozolomide-resistant GSCs, especially under hypoxia. Furthermore, it decreased invasion of glioblastoma cell spheroids. Conclusions This in vitro study provides novel insights on the links between sphingolipid metabolism and invasion, a hallmark of cancer, and cancer stem cells, key drivers of cancer. It demonstrates the therapeutic potential of approaches that combine modulation of sphingolipid metabolism with first-line agent temozolomide in overcoming tumor growth and relapse by reducing hypoxia-induced resistance to chemotherapy and by targeting both differentiated and stem glioblastoma cells." @default.
• W4385872145 created "2023-08-17" @default.
• W4385872145 creator A5002244815 @default.
• W4385872145 creator A5019233746 @default.
• W4385872145 creator A5054823577 @default.
• W4385872145 creator A5065196154 @default.
• W4385872145 creator A5086925656 @default.
• W4385872145 creator A5091635843 @default.
• W4385872145 date "2023-08-16" @default.
• W4385872145 modified "2023-10-03" @default.
• W4385872145 title "Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion" @default.
• W4385872145 cites W1535187116 @default.
• W4385872145 cites W1602005811 @default.
• W4385872145 cites W1963866971 @default.
• W4385872145 cites W1968601707 @default.
• W4385872145 cites W1970504457 @default.
• W4385872145 cites W1977811325 @default.
• W4385872145 cites W1980454471 @default.
• W4385872145 cites W1986655234 @default.
• W4385872145 cites W1993427232 @default.
• W4385872145 cites W1996800032 @default.
• W4385872145 cites W2006117045 @default.
• W4385872145 cites W2009993180 @default.
• W4385872145 cites W2017729786 @default.
• W4385872145 cites W2023595695 @default.
• W4385872145 cites W2023846533 @default.
• W4385872145 cites W2025370055 @default.
• W4385872145 cites W2027151723 @default.
• W4385872145 cites W2027542963 @default.
• W4385872145 cites W2039386747 @default.
• W4385872145 cites W2041868010 @default.
• W4385872145 cites W2045583102 @default.
• W4385872145 cites W2052083735 @default.
• W4385872145 cites W2052561616 @default.
• W4385872145 cites W2064194224 @default.
• W4385872145 cites W2065140134 @default.
• W4385872145 cites W2077945404 @default.
• W4385872145 cites W2079203845 @default.
• W4385872145 cites W2079959709 @default.
• W4385872145 cites W2082517062 @default.
• W4385872145 cites W2096287682 @default.
• W4385872145 cites W2096439168 @default.
• W4385872145 cites W2101364134 @default.
• W4385872145 cites W2116896168 @default.
• W4385872145 cites W2117773251 @default.
• W4385872145 cites W2121396361 @default.
• W4385872145 cites W2133190342 @default.
• W4385872145 cites W2135925682 @default.
• W4385872145 cites W2151385495 @default.
• W4385872145 cites W2154451644 @default.
• W4385872145 cites W2157051245 @default.
• W4385872145 cites W2157247642 @default.
• W4385872145 cites W2158681922 @default.
• W4385872145 cites W2159171427 @default.
• W4385872145 cites W2161289668 @default.
• W4385872145 cites W2165871546 @default.
• W4385872145 cites W2327560994 @default.
• W4385872145 cites W2530193963 @default.
• W4385872145 cites W2552037661 @default.
• W4385872145 cites W2579905165 @default.
• W4385872145 cites W2610739723 @default.
• W4385872145 cites W2752326209 @default.
• W4385872145 cites W2768617092 @default.
• W4385872145 cites W2789174387 @default.
• W4385872145 cites W2922723063 @default.
• W4385872145 cites W2949573434 @default.
• W4385872145 cites W2951880440 @default.
• W4385872145 cites W3121493180 @default.
• W4385872145 cites W3152734184 @default.
• W4385872145 cites W4220990978 @default.
• W4385872145 doi "https://doi.org/10.1186/s12885-023-11271-w" @default.
• W4385872145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37587449" @default.
• W4385872145 hasPublicationYear "2023" @default.
• W4385872145 type Work @default.
• W4385872145 citedByCount "0" @default.
• W4385872145 crossrefType "journal-article" @default.
• W4385872145 hasAuthorship W4385872145A5002244815 @default.
• W4385872145 hasAuthorship W4385872145A5019233746 @default.
• W4385872145 hasAuthorship W4385872145A5054823577 @default.
• W4385872145 hasAuthorship W4385872145A5065196154 @default.
• W4385872145 hasAuthorship W4385872145A5086925656 @default.
• W4385872145 hasAuthorship W4385872145A5091635843 @default.
• W4385872145 hasBestOaLocation W43858721451 @default.
• W4385872145 hasConcept C170493617 @default.
• W4385872145 hasConcept C190283241 @default.
• W4385872145 hasConcept C203522944 @default.
• W4385872145 hasConcept C2776596873 @default.
• W4385872145 hasConcept C2777389519 @default.
• W4385872145 hasConcept C2777700496 @default.
• W4385872145 hasConcept C2777851122 @default.
• W4385872145 hasConcept C2778227246 @default.
• W4385872145 hasConcept C2778703144 @default.
• W4385872145 hasConcept C31573885 @default.
• W4385872145 hasConcept C502942594 @default.
• W4385872145 hasConcept C55493867 @default.
• W4385872145 hasConcept C61705674 @default.
• W4385872145 hasConcept C86803240 @default.
• W4385872145 hasConcept C95444343 @default.
• W4385872145 hasConcept C98274493 @default.
• W4385872145 hasConceptScore W4385872145C170493617 @default.

• next